Tevogen Bio (TVGN) Financials

Tevogen Bio’s latest quarter shows a company still deep in pre-revenue development mode, with losses continuing and cash burn remaining a major issue. In Q1 2026, TVGN reported no revenue, a net loss of $5.4 million, and negative operating cash flow of $2.7 million. The company did add cash during the quarter, but that was driven by $2.0 million of debt issuance and $873,702 of common equity issuance, not by operations.

Over the past four years, the financial trend is clear: Tevogen Bio has not generated revenue, continues to post sizable quarterly losses, and depends on external financing to fund operations. At the same time, operating expenses have fallen sharply from the huge levels seen in early 2024, which may indicate tighter cost control. Still, the balance sheet remains under pressure, with negative shareholders’ equity and meaningful liabilities relative to assets.

• Operating expenses have declined materially from the extreme levels seen in early 2024, suggesting management has reduced spending from its prior peak.
• Q1 2026 cash and equivalents rose slightly to $692,305, helped by financing inflows.
• The company generated positive financing cash flow in Q1 2026, including $2.0 million of debt and $873,702 of equity.
• Compared with early 2024, quarterly net losses are much smaller, which shows the business is no longer burning capital at the same scale as its most expensive period.
• The company remains in a pre-revenue stage, so there is no top-line growth to evaluate yet.
• Research and development spending is still significant, at $3.1 million in Q1 2026, which is normal for a biotech company but continues to pressure results.
• Depreciation and amortization are relatively small compared with total losses, so most of the deficit is coming from operating expenses rather than non-cash charges.
• The share count has changed dramatically over the last year, making per-share comparisons less meaningful and suggesting heavy dilution risk.
• Q1 2026 revenue was $0, and the company still has not shown a commercial business.
• TVGN posted a $5.4 million net loss in Q1 2026 and an operating loss of $5.4 million.
• Operating cash flow was negative $2.7 million in Q1 2026, meaning the core business is still consuming cash.
• The balance sheet shows negative common equity of $18.6 million and total liabilities of $14.8 million versus total assets of just $4.9 million.
• Current liabilities of $7.3 million exceed current assets of $2.1 million, pointing to weak near-term liquidity.
• The company continues to rely on financing to stay afloat, which raises the risk of future dilution or additional debt.

Bottom line: Tevogen Bio’s financials still look highly speculative. The good news is that spending has come down from prior peaks, but the company remains unprofitable, cash-consuming, and dependent on capital raises. Until TVGN can generate revenue or show a clearer path to commercialization, the stock will likely remain a high-risk story for retail investors.